RxDoctor Payments Data

Willis Wu, MD

Interventional Cardiology · Raleigh, NCNPI 1184840514

Payments from drug & device makers

What this record shows

The money is spread across several categories — speaking fees (53.0%), consulting fees and travel and lodging — rather than concentrated in one kind of arrangement. 18 manufacturers reported payments, led by Medtronic at 54.4% of the total. Reporting peaked in 2023 at $20,294 and has fallen 97.3% since, to $549 in 2025.

$55,949in general payments, 2019–2025

Across 188 payments — averaging $297.60 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Medtronic$30K
  • Edwards Lifesciences$8K
  • Abbott$6K
  • Cordis US CORP.$4K
  • Boston Scientific$4K
  • Ancora Heart, Inc.$3K
  • plus $461 from 12 others
$614,791in research payments, 2019–2025

Across 172 payments — averaging $3574.37 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • Penumbra, Inc.$365K
  • Boston Scientific$132K
  • Abbott$57K
  • Edwards Lifesciences$53K
  • Philips North America LLC$8K

What the payments were for

  • Consulting fees$13,27524%
  • Speaking & faculty fees$29,63853%
  • Grants$1000%
  • Travel & lodging$8,14615%
  • Food & beverage$4,7909%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$55,949 in reported general payments places this provider in the 85th percentile of 180 interventional cardiology providers in North Carolina.

See all interventional cardiology providers in North Carolina

Medicare billing

Part B allowed, 2024
$332,897
Medicare patients
670
Services billed
2,018

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban127$113,487
EntrestoSacubitril/Valsartan51$52,408
Repatha SureclickEvolocumab15$17,319
XareltoRivaroxaban21$13,279
JardianceEmpagliflozin16$10,466
Ranolazine ErRanolazine32$4,421
Atorvastatin Calcium199$1,850
Metoprolol Succinate138$1,687
Rosuvastatin Calcium135$1,522
Isosorbide Mononitrate ErIsosorbide Mononitrate65$1,405
ClopidogrelClopidogrel Bisulfate192$1,291
Potassium Chloride43$1,166
Prasugrel Hcl25$913
Spironolactone84$883
Furosemide115$692

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$97$113,487127 claims
NovartisEntresto$17$52,40851 claims
Johnson & JohnsonXarelto$76$13,27921 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 180 interventional cardiology providers in North Carolina.

Other interventional cardiology in Raleigh

See the full list for North Carolina

Where these figures come from

Is this you, or does something look wrong? →